Category: Pharma Industry

Novo Nordisk to Provide 340B Refunds on Hemophilia Drugs

December 14, 2023 Rich Daly, Editor in Chief Views

Novo Nordisk will issue 340B provider refunds for formulations of two hemophilia drugs, according to a HRSA manufacturer notice.

Novo Nordisk will issue its fifth round of refunds this year on prices charged to 340B providers. The latest are [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Legislation ‘Is Coming’ to Address Contract Pharmacy Restrictions, Hospital Advocate Says

December 12, 2023 Rich Daly, Editor in Chief Views

Maureen Testoni, president and CEO of 340B Health, said she anticipates bipartisan legislation on drugmaker 340B contract pharmacy restrictions.

Months after it was expected, bipartisan legislation to prevent drugmaker restrictions on the use of contract pharmacies by 340B providers [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Missouri State Senator to Reintroduce 340B Contract Pharmacy, PBM Protection Bill

December 12, 2023 William Newton, Associate Editor/Senior Writer Views

The Missouri state senate recently passed a 340B contract pharmacy access bill.

A Missouri state senator has filed to reintroduce a bill that would bar drugmaker 340B contract pharmacy restrictions and pharmacy [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Drugmakers Highlight 340B Developments in Earnings Calls

December 12, 2023 Rich Daly, Editor in Chief Views

Jean-Jacques Bienaime, CEO of drugmaker BioMarin, discussed the impact of 340B on pharmaceutical sales during an investor earnings call.

Pharmaceutical company executives discussed a range of 340B-related developments in recent third quarter investor calls. An executive for BioMarin Pharmaceutical, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Amid Record Drugmaker Refunds, No Adverse Audit Findings for Teva

December 7, 2023 Rich Daly, Editor in Chief Views

The final HRSA manufacturer 340B program audit conducted in fiscal year 2023 had no adverse findings for Teva Pharmaceuticals.

The fifth and final fiscal year 2023 manufacturer audit by federal officials recently concluded with no adverse findings. Meanwhile, the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Two Senior GOP Senators Suggest 340B Linked to Generic Drug Shortages

December 7, 2023 William Newton, Associate Editor/Senior Writer Views

Sen. Mike Crapo (R-Idaho), ranking member of the Senate Finance Committee, said penny pricing under 340B warranted “serious scrutiny in the context of generic products.”

Two Republican Senators on an influential committee suggested during a hearing on Tuesday that 340B discounts could contribute to certain [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Four 340B Terminations, Eight Paybacks to Manufacturers in Latest Provider Audit Findings

December 5, 2023 Rich Daly, Editor in Chief Views

Federal auditors determined terminations from the 340B program were required for either covered entity sites or a contract pharmacy of two more 340B providers.

Federal auditors determined terminations from the 340B program were required for either covered entity sites or contract pharmacies of four [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Biogen Adds Drug with Narrow Approval to 340B Contract Pharmacy Restrictions

December 5, 2023 Rich Daly, Editor in Chief Views

Drugmaker Biogen recently added a third drug to its 340B contract pharmacy restrictions for hospitals.

Biopharmaceutical manufacturer Biogen recently expanded its contract pharmacy restrictions for hospitals to a third drug, after that medication garnered a [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Arkansas, Novo Nordisk Clash Over Court’s Role in Contract Pharmacy Law Enforcement

December 5, 2023 William Newton, Associate Editor/Senior Writer Views

Novo Nordisk and the Arkansas Insurance Department are at odds over whether a federal district court should intervene in the enforcement of Arkansas' 340B contract pharmacy law.

Novo Nordisk and the Arkansas Insurance Department (AID) are sparring in court over whether a federal district court should hear [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Reforms Needed, Says Former Presidential Candidate, Drug Industry Consultant

December 5, 2023 Rich Daly, Editor in Chief Views

Howard Dean, a former Democratic presidential candidate who has consulted for the drug industry, said the 340B program is in need of reforms.

The 340B program has become “a multibillion-dollar boondoggle for hospital mega-chains” and needs reform, says Howard Dean, a one-time Democratic [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Site Footer Live